Navigation Links
Access Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference
Date:11/6/2008

c agent that combines multiple modes of action to overcome drug resistance. Access is also developing Phenylbutyrate ("PB"), an HDAC inhibitor and differentiating agent currently a Phase 2 clinical candidate. For additional information on Access Pharmaceuticals, please visit our website at http://www.accesspharma.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: early results from our clinical trial, Access' plans to continue and initiate clinical trials, the value of its products in the market, its ability to achieve clinical and commercial success and its ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited Access' need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access' Annual Reports on Form 10-K and other reports filed by Access with the Securities and Exchange Commission.


'/>"/>
SOURCE Access Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Radiation Therapy Oncology Group and US Oncology Enter Collaboration to Increase Patient Access to National Clinical Trials
2. GeoVax Labs, Inc. Information To Be Available Through Standard & Poors Market Access Program
3. Mymetics Corporation Information to be Available Through Standard & Poors Market Access Program
4. Access Pharmaceuticals Licenses MuGard to Milestone Biosciences, LLC for North America
5. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
6. NxStage Announces Access to Demographic and Outcomes Information for the Growing U.S. Daily Home Hemodialysis Patient Population
7. Roche starts acquisition process of ARIUS to gain access to new screening platform for antibody therapeutics
8. AMT Starts Collaboration With St. Jude Childrens Research Hospital on Gene Therapy for Hemophilia B. Company Accesses Exclusive Commercial Rights to Final Therapy
9. Access Pharmaceuticals Signs Merger Agreement to Acquire MacroChem Corp.
10. Huifeng Bio-Pharmaceutical (HFGB) Information to Be Available Through Standard & Poors Market Access Program
11. Access Pharmaceuticals Presents New Data at International Symposium Showing Companys Angiolix(R) Monoclonal Antibody has Potential to Treat Cancer by Attacking Cancer Stem Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Geneva, Switzerland (PRWEB) January 22, 2015 ... for characterized mammalian Research Cell Banks (RCBs) used for ... generated Research Cell Banks will include Next-Generation Sequencing ... cell’s genetic architecture de-risks biologic manufacturing by ensuring the ...
(Date:1/22/2015)... 22. 2015  Varian Medical Systems (NYSE: VAR ), ... for its commitment to sustainability with inclusion on a prestigious ... highest ranked healthcare equipment company among the Corporate Knights Global ... Economic Forum at Davos, Switzerland . ...
(Date:12/24/2014)... SILVER SPRING, Md. , Dec. 24, 2014  United ... that Medtronic, Inc. (NYSE: MDT ) has ... and Drug Administration (FDA) for the use of Medtronic,s ... a newly developed catheter) for use with United Therapeutics, ...
(Date:12/24/2014)... December 23, 2014 “Preparative & ... HPLC, Flash), Consumables (Columns, Solvents, Buffers, Valves, Guages, ... & Agriculture) - Forecasts to 2019” provides a ... opportunities, current market trends, and strategies impacting the ...
Breaking Biology Technology:Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2Varian Honored Among World's 100 Most Sustainable Corporations 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4
... 7 /PRNewswire-FirstCall/ - Dragon Pharmaceutical Inc. ("Dragon" or the ... receipt of preliminary proxies, the Company believes that it has ... ("Merger") by and among Dragon, Chief Respect Limited, Datong Investment ... Yanlin Han . The Merger must be approved by holders ...
... , , ... a 25 percent replacement for petroleum oil more than doubles rubber,s stretchability and reduces its environmental ... Ford,s ... automotive parts such as deflector shields and baffles, radiator deflector shields, cupholder inserts and floor mats ...
... DATATRAK International, Inc. (OTCQX: DATA), a technology and services ... industry, today announced that it privately placed 357,857 common shares ... with certain members of its Board of Directors and management ... are restricted securities and are subject to the restrictions on ...
Cached Biology Technology:Dragon Pharma announces receipt of preliminary proxies to approve merger 2Dragon Pharma announces receipt of preliminary proxies to approve merger 3Ford Pioneers Patent-Pending Use of Eco-Friendly Soy Oil in Rubber Automotive Parts 2Ford Pioneers Patent-Pending Use of Eco-Friendly Soy Oil in Rubber Automotive Parts 3Ford Pioneers Patent-Pending Use of Eco-Friendly Soy Oil in Rubber Automotive Parts 4DATATRAK Completes Sale of 357,857 Common Shares to Directors and Management 2DATATRAK Completes Sale of 357,857 Common Shares to Directors and Management 3
(Date:12/17/2014)... , Dec. 15, 2014 Research and Markets ... the "Samsung Galaxy S5 - Home Button Synaptics ... http://photos.prnewswire.com/prnh/20130307/600769 ... iPhone 5S, Samsung introduces for the first time a ...
(Date:12/17/2014)... NEW YORK , Dec. 15, 2014  HITLAB SM ... Practices (GCP) audit to confirm its adherence to current ... enables HITLAB to conduct regulated smart device and smart ... safety and research quality. "HITLAB is determined ...
(Date:12/17/2014)... Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ) has announced the ... report to their offering. ... in this market is the increasing demand for medical ... of patient data for quick and correct diagnosis during ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2
... to be essential in helping chemotherapy kill cancer cells, may ... patients, scientists at the Georgia Institute of Technology and the ... tumors had mutations in the gene p53 were still alive ... 30 percent survival rate. The findings raise the possibility of ...
... and tasty, but don’t count on them to ... of Cancer Epidemiology, Biomarkers & Prevention, researchers based ... Cancer Research Center report that lycopene, an antioxidant ... prostate cancer. In fact, the researchers noted ...
... in the prestigious international journal, the British Journal of ... be explained by increases in clinical reasons for caesareans ... more likely due to societal factors. , The research ... 1984 and 2003 (more than 430,000 births) and ...
Cached Biology News:Gene thought to assist chemo may help cancer thrive 2Gene thought to assist chemo may help cancer thrive 3No magic tomato? Study breaks link between lycopene and prostate cancer prevention 2Study shows dramatic increase in Caesarean sections 2
Chaps Cell Extract Buffer can be used to lyse cells under nondenaturing conditions and is recommendedfor the preparation of cell lysates to be used with our caspase signaling pathway antibodies...
...
Jak3 Antibody Ship: Hot Store: -20 C...
WASF2 Immunogen: WASF2 (NP_008921, 73 a.a. ~ 173 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Biology Products: